| γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct Y Ran, F Hossain, A Pannuti, CB Lessard, GZ Ladd, JI Jung, LM Minter, ... EMBO molecular medicine 9 (7), 950-966, 2017 | 138 | 2017 |
| Alzheimer’s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph L Magno, CB Lessard, M Martins, V Lang, P Cruz, Y Asi, M Katan, ... Alzheimer's research & therapy 11, 1-11, 2019 | 133 | 2019 |
| High‐affinity interactions and signal transduction between Aβ oligomers and TREM 2 CB Lessard, SL Malnik, Y Zhou, TB Ladd, PE Cruz, Y Ran, TE Mahan, ... EMBO molecular medicine 10 (11), e9027, 2018 | 118 | 2018 |
| The overexpression of presenilin2 and Alzheimer's-disease-linked presenilin2 variants influences TRPC6-enhanced Ca2+ entry into HEK293 cells CB Lessard, MP Lussier, S Cayouette, G Bourque, G Boulay Cellular signalling 17 (4), 437-445, 2005 | 92 | 2005 |
| Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein SA Sagi, CB Lessard, KD Winden, H Maruyama, JC Koo, S Weggen, ... Journal of Biological Chemistry 286 (46), 39794-39803, 2011 | 43 | 2011 |
| Individual and combined presenilin 1 and 2 knockouts reveal that both have highly overlapping functions in HEK293T cells CB Lessard, E Rodriguez, TB Ladd, LM Minter, BA Osborne, L Miele, ... Journal of Biological Chemistry 294 (29), 11276-11285, 2019 | 19 | 2019 |
| Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions CL Croft, MS Goodwin, DH Ryu, CB Lessard, G Tejeda, M Marrero, ... Acta Neuropathologica 141, 359-381, 2021 | 17 | 2021 |
| γ-secretase modulators and APH1 isoforms modulate γ-secretase cleavage but not position of ε-cleavage of the amyloid precursor protein (APP) CB Lessard, BA Cottrell, H Maruyama, S Suresh, TE Golde, EH Koo PLoS One 10 (12), e0144758, 2015 | 17 | 2015 |
| A nuclear function for the presenilin 1 neuronal partner NPRAP/δ-catenin C Koutras, CB Lessard, G Lévesque Journal of Alzheimer's Disease 27 (2), 307-316, 2011 | 17 | 2011 |
| And four equals one: Presenilin takes the γ-secretase role by itself CB Lessard, SL Wagner, EH Koo Proceedings of the National Academy of Sciences 107 (50), 21236-21237, 2010 | 14 | 2010 |
| Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways KR Ibanez, KN McFarland, J Phillips, M Allen, CB Lessard, L Zobel, ... Alzheimer's Research & Therapy 14 (1), 104, 2022 | 11 | 2022 |
| γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not CB Lessard, E Rodriguez, TB Ladd, LM Minter, BA Osborne, L Miele, ... Alzheimer's Research & Therapy 12, 1-8, 2020 | 8 | 2020 |
| Ryanoids and related compounds Isolation and characterization of 11 new minor ryanoids from the plant Ryania Speciosa Vahl L Ruest, M Dodier, H De Sève, C Lessard, P Mongrain Canadian journal of chemistry 80 (5), 483-488, 2002 | 4 | 2002 |
| High-affinity interactions and signal transduction between Abeta oligomers and TREM2. EMBO Mol Med. 2018; 10 CB Lessard, SL Malnik, Y Zhou, TB Ladd, PE Cruz, Y Ran | 2 | |
| Hypomorphic PERK promotes a maladaptive phenotype in response to pathologic tau CB Lessard, SG Tolton, JFF Abisambra Alzheimer's & Dementia 18, e068002, 2022 | 1 | 2022 |
| Étude sur la régulation et de la voie moléculaire de la Béta-sécrétase et de préséniline C Lessard Université Laval, 2010 | 1 | 2010 |
| Tau‐RNA complexes contribute to the pathogenesis and progression in Alzheimer’s disease and related tauopathies CB Lessard, J Koren III, JFF Abisambra Alzheimer's & Dementia 18, e069399, 2022 | | 2022 |
| Targeting aggregated tau turnover as a therapeutic strategy CL Croft, MS Goodwin, DH Ryu, CB Lessard, G Tejeda, M Marrero, ... Alzheimer's & Dementia 17, e056366, 2021 | | 2021 |
| Tracking the formation and fate of tau inclusions in neurodegenerative tauopathies CL Croft, MS Goodwin, DH Ryu, CB Lessard, G Tejeda, M Marrero, ... AAIC Neuroscience Next, 2020 | | 2020 |
| Therapeutic Targeting of Aβ42 TE Golde, CB Lessard, Y Ran Developing Therapeutics for Alzheimer's Disease, 77-96, 2016 | | 2016 |
